Edaravone in the Treatment of Optic Neuritis

ConditionOptic Neuritis

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-70

SponsorFirst Affiliated Hospital of Guangxi Medical University

About this trial

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Eligibility criteria

Qualifiers

Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis

Patients with a first episode of optic neuritis in either eye

First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

Disqualifiers

Myopia over 6 diopters

Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Trial design

Treatments tested in this trial

Edaravone

Treatment groups

50 Participants

are divided into 1 treatment group

Sponsors and collaborators

First Affiliated Hospital of Guangxi Medical University

Lead sponsor

Source ClinicalTrials.gov